Cargando…

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy

In chronic lymphocytic leukaemia (CLL), immune dysregulation is common and can manifest as immune thrombocytopenia (ITP). Corticosteroids are the mainstay for front-line management of CLL-associated ITP. Therapy refractoriness represents a clinical challenge and is an indication to commence CLL-dire...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woo, Timothy, Carter, Matthew, Follows, George, Patten, Piers EM.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619646/ https://www.ncbi.nlm.nih.gov/pubmed/37920161 http://dx.doi.org/10.3389/fonc.2023.1260003

Ejemplares similares

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Trastuzumab Associated With Recurrent Severe Thrombocytopenia and Successful Use of Pertuzumab Monotherapy
por: Huff, Mallorie L, et al.
Publicado: (2022)

Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
por: Guarente, Valerio, et al.
Publicado: (2021)

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
por: Lovato, Ester, et al.
Publicado: (2023)

PB1889: A CASE OF REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA INDUCED IMMUNE THROMBOCYTOPENIC PURPURA SUCCESSFULLY TREATED WITH VENETOCLAX
por: Yavuz, B., et al.
Publicado: (2022)

Venetoclax and Azacitidine in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory to Conventional Therapy
por: Azad, Farhan, et al.
Publicado: (2022)

Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia
por: Carrà, Giovanna, et al.
Publicado: (2019)

Practical management of tumour lysis syndrome in venetoclax‐treated patients with chronic lymphocytic leukaemia
por: Gribben, John G.
Publicado: (2019)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021)

Successful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab
por: Jung, Chul Won, et al.
Publicado: (2016)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
por: Wang, Bin-Ru, et al.
Publicado: (2021)

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia
por: Sarapura Martinez, Valeria J., et al.
Publicado: (2023)

Mechanisms of venetoclax resistance and solutions
por: Liu, Jiachen, et al.
Publicado: (2022)

Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
por: Jackson, Ross A., et al.
Publicado: (2022)

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy
por: Popovic, Relja, et al.
Publicado: (2021)

Ocular toxoplasmosis during frontline venetoclax therapy for chronic lymphocytic leukaemia – more than meets the eye
por: Bennett, Rory, et al.
Publicado: (2023)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
por: Tenold, Matthew E., et al.
Publicado: (2021)

Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1
por: Fiorcari, Stefania, et al.
Publicado: (2022)

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2017)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies
por: Khan, Sujoy, et al.
Publicado: (2023)

Refractory Autoimmune Cytopenias Treated With Venetoclax
por: Gordon, Max J., et al.
Publicado: (2019)

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report
por: Long, Zhangbiao, et al.
Publicado: (2022)

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
por: Ceglédi, Andrea, et al.
Publicado: (2023)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Abnormal Chromatin Clumping in Myeloblasts Mimicking Chronic Lymphocytic Leukaemia: A Diagnostic Pitfall
por: Sehgal, Tushar, et al.
Publicado: (2021)

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)

Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2019)

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)

Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax
por: Teoh, Ching Soon, et al.
Publicado: (2021)

NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia
por: Edelmann, Jennifer
Publicado: (2022)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi
por: Ballotta, Laura, et al.
Publicado: (2021)

A Case of Refractory Polymyositis Successfully Treated With Abatacept Monotherapy
por: ÇAĞLAYAN, Mehmet, et al.
Publicado: (2020)

Refractory immune thrombocytopenia. Successful treatment with repeated cyclosporine A: two case reports
por: Hlusi, Antonin, et al.
Publicado: (2015)

Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
por: Anwer, Faiz, et al.
Publicado: (2015)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
por: Vereertbrugghen, Alexia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6b63ejd6ggajf7drahsm5lip1b